Royalty Pharma：FDA批准Cytokinetics的MYQORZO（aficamten）用于oHCM

FDA批准了MYQORZO（aficamten）用于症状性梗阻性肥厚型心肌病的NDA。Royalty Pharma现在可从销售中获得4.5%的特许权使用费（最高50亿美元），之后为1%，此外还有2.75亿美元已提取资金的1.9倍偿还，期限10年。Cytokinetics可在12个月内额外提取1.75亿美元，从而触发进一步的1.9倍偿还。

关键事实

申报时间: 2025年12月22日 16:37
事件: FDA 批准
方向: 积极
公司: RPRXRoyalty Pharma
资产: aficamten
来源: SEC 8-K
可信度: 有来源

来源摘录

8-K NY false 0001802768 0001802768 2025-12-19 2025-12-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Royalty Pharma plc (Exact Name of Registrant as Specified in its Charter) England and Wales 001-39329 98-1535773 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Identification No.) 110 East 59 th Street New York , New York 10022 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (212) 883-0200 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if

SEC 8-K